cosmo
Well-Known Member
Only 1/3rd of the infected patients met their inclusion criteria, but they don't mention the criteria. Also, the mortality rate of patients with no pre-existing conditions is thought to be around .9%. I can't find data for an age range to make a comparison to those who passed away in this study. But this "study" is incomplete.The new study, of which the abstract was released today, was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the Hydroxychloroquine-Azithromycin (HCQ-AZ) combination and a follow-up of at least 9 days was investigated.
Key findings are:
- No cardiac toxicity was observed.
A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more.
- A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%).
The authors conclude that:
“The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.”
http://covexit.com/professor-didier...chloroquine-treatment-study-on-1061-patients/
Trump retweeted a firefauci message. What a great idea, typical for a great leader right?
Sponsored